Tucatinib comment watch save

  • FDA APPROVAL DATE: 04/17/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    CYP2C8 Inducers, CYP2C8 Inhibitors, CYP3A Inducers, CYP3A Substrates, CYP3A Substrates, Digoxin, Gemfibrozil, Itraconazole, Metformin, Midazolam, P-gp Substrates, Repaglinide, Rifampin
  • PREGNANCY: Tucatinib can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to the fetus.

Please login to view the rest of this drug profile.

Page last updated 08/21/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top